GINZA NOA CLINIC
Tokyo, Japan International Patient Support
Contact Us

What Should My Local Doctor Receive?

After stem cell treatment in Japan, your local doctor should receive a written discharge summary and follow-up plan in a language they can use, usually English for international care. Ask for 8 core items: diagnosis, procedure note, cell product details, regulatory status, before-and-after medicine lists, key test results, a follow-up plan with warning signs, and a contact for medical questions. Keep the Japanese originals and a copy for yourself.

Before discharge, check the documents rather than assuming the set is complete. Confirm cell type, cell source, whether cells were cultured, medicine changes, and the next review date in writing.

What Should My Local Doctor Receive?

A spoken recap or payment receipt cannot replace a clinical handover. Your local doctor needs records they can use for prescriptions, monitoring, rehabilitation, referrals, and urgent decisions.

Why the handover matters

Depending on the procedure, care may involve tissue collection, cell processing, an injection or surgery, anesthesia, or changes to medicines. The handover should state what actually happened and any complications, not just what was planned. That helps your doctor assess a fever, review a paused medicine, or arrange follow-up without relying on your memory.

Set up the handover before you travel

Loop your local doctor in early, so the return handover has something to build on. Share your confirmed diagnosis and its date, what you take now and what you are allergic to, and which standard options you have tried or turned down. Then ask two plain questions and write down what you hear: whether the trip, the break in current treatment, or the planned procedure is unsafe for you, and what your doctor will want to see when you are back. Put that note right on top of the Japanese packet later, so baseline information comes first.

What the handover should contain

Ask the Japanese clinic for a written discharge and follow-up set in English, with dates no one can misread. Where the original is Japanese, get at least the summary pages translated and keep both versions clipped together. Check that each page shows the day the examination or procedure really happened — not just the day it was reported or sent.

Use the 8-item checklist below before discharge. These are suggested handover contents, not a universal legal document requirement; ask your local doctor whether anything else is needed.

DocumentWhat it should containWhy your doctor needs it
Discharge or treatment summaryClinic and doctor name, dates of care, confirmed diagnosis, purpose of the visitEstablishes what happened, where, and when
Procedure noteCollection site and method if tissue was taken, processing or culture steps, administration route and site, dates, anesthesia, and any complications with treatment givenShows what was actually done to the body, not just what was planned
Cell product descriptionCell type, source (your own cells or donor cells), whether cells were cultured, product name if a named product was used, dose and number of sessions if applicablePrevents vague labels such as stem cells from hiding very different products
Regulatory status in plain wordsProduct name and approved indication if approval is claimed; otherwise the provision-plan or study identifier and whether the intervention is experimental. A private-clinic service is not automatically an approved treatment.Distinguishes product approval from a provision plan or study registration; these are not equivalent evidence of efficacy. [1]
Medicine list before and afterMedicine names, doses, frequency, allergies, what was stopped, started, or changed, why, and any written restart or stop instructionsAllows safe repeat prescribing and avoids interactions
Test resultsKey blood tests, imaging reports, pathology, and any baseline and post-treatment measurements with units and reference rangesLets the doctor compare before and after without repeating everything
Follow-up plan with warning signsWound care, activity limits, rehabilitation, tests and review dates, who is responsible, expected effects, warning signs, urgent-care instructions, and travel advice if givenTurns a trip into a care plan
Contacts and consent for follow-up questionsNamed contact for medical queries, preferred language, and your written permission for the two sides to exchange informationMakes a later phone call or letter possible under privacy rules

The cell source changes the meaning of the record. NCI describes blood-forming stem cell transplantation as restoring blood production after high-dose chemotherapy or radiation for selected cancers and other disorders. Graft-versus-host disease is a risk of donor (allogeneic) transplantation, not a general risk to attach to every cell injection. [2] NCI describes infusion taking 1 to 5 hours and recovery lasting months, sometimes with hospital visits two or three times a week after discharge. Those schedules describe transplantation, not a standard timetable for private-clinic cell procedures. [2]

What changes in Japan

Care settings

A university hospital, a large specialist hospital, and a private clinic do not run on one set of referral or discharge rules. So expect a private-clinic discharge to read differently from your home hospital’s paperwork.

Language and format

Keep the Japanese originals stapled to the English versions. Keep each scan report with its actual image files, marked by body part, left or right side, and date done. The report and the files are two different things, and your doctor often needs both.

Regulation wording

Japan has two regulatory frameworks: the safety framework for provision and research, and the PMD Act framework for regenerative medical product approval. A reviewed provision plan is not the same as product approval and does not establish that an intervention works for your diagnosis. Ask for the actual product, plan, or study identifier rather than relying on a “registered clinic” label. [1] PMDA’s presentation dated May 20, 2026 reported 26 approved regenerative medical products under the PMD Act across the whole category. This is a historical count, not a current tally or an endorsement of a clinic’s treatment; check the specific product and approved indication. [3]

Payment

Get the price and what it covers in writing, and confirm coverage with your insurer before travel. Keep the itemized bill separate from the clinical summary: each serves a different purpose.

What does not count as a handover

Run every page through one question: does it state the diagnosis, the procedure, or the follow-up? A receipt gives none of that, and neither does a glossy brochure or a set of phone snaps of a scan. The same goes for a kind letter saying treatment went well that lists no dates, no product detail, no medicine changes, and no next steps.

Bulk alone fails too. A thick folder with no summary just sits there. Ask the clinic to put a one- or two-page summary on top — something a busy doctor can read in minutes — with the full reports behind it. Your own one-page timeline of symptoms, travel dates, and worries makes a useful cover sheet, though it cannot stand in for the original records.

How to get the handover from the clinic

Send the clinic a specific request before discharge rather than “please send everything.” You can adapt this wording:

Please provide an English discharge summary and follow-up plan I can give my local doctor. Please include diagnosis, procedure note, cell type and source, whether cells were cultured, product name if applicable, regulatory status of the care, medicine changes, key test results with units, wound and activity instructions, rehabilitation plan, warning signs, and a contact for medical follow-up questions. Please include dates the examinations and procedures were actually performed.

Check your name, date of birth, treated side, allergies, and medicine doses while staff can still correct errors. For each key blood test, request the date, test name, result, unit, and reference range. Ask how to obtain original imaging files and any relevant pathology material, and agree who will answer medical questions, in what language, and through which secure channel.

For a practical example, suppose the discharge list says a blood thinner was paused but gives no restart instruction. Before leaving, ask the treating clinician to document the medicine, dose, reason for the pause, and who will decide when to restart it. Do not supply the missing instruction yourself. This is an illustrative paperwork check, not a patient case or a medication recommendation.

What your doctor does with the handover

Agree in advance which clinician will handle medicine review, tests, rehabilitation, and questions after you return. Your local doctor may need specialist advice rather than taking over every aspect of care.

Bring the before-and-after medicine lists, especially for blood thinners, diabetes medicines, steroids, immunosuppressants, antibiotics, and painkillers. Ask your doctor to review the written plan; do not change doses yourself to fill a gap in the paperwork. Test timing, activity limits, and rehabilitation should match the actual procedure and your condition, not the broad label “stem cell therapy.”

The FDA reports serious harms from unapproved regenerative products, including blindness, tumors, and infections; its warning covers products involving a person’s own cells as well as donor material. This is a US warning, not a finding about a particular Japanese clinic. [4] Ask the treating team to specify warning signs and urgent-care instructions for your procedure. Symptoms to discuss include:

  • Fever
  • Spreading redness
  • Severe or worsening pain
  • Chest pain or trouble breathing
  • Vision changes
  • Weakness or numbness
  • Loss of bladder or bowel control

New chest pain, trouble breathing, sudden vision loss, new weakness, or loss of bladder or bowel control warrants emergency assessment. For fever, spreading redness, or worsening pain, seek prompt medical advice according to the discharge instructions. Do not wait for an overseas email reply if symptoms are severe or rapidly worsening.

Sharing the handover across borders

Ask both providers what permission they need to exchange medical information; requirements depend on the jurisdiction and the purpose of disclosure. Record the named recipient, what may be shared, and whether a coordinator or interpreter may see clinical details. Use a provider-approved secure channel, keep a copy, and carry the summary and medicine list when traveling. The site’s health data and medical records policy and third-party disclosure information describe its arrangements, not a universal cross-border legal rule.

If your doctor doubts the papers

Ask which evidence is missing. An approval claim needs the exact product and indication; a research claim needs the study identifier and relevant results, not just a registration number. The FDA’s US consumer warning illustrates why broad claims about unapproved regenerative products deserve scrutiny, but it does not determine the status of care in Japan. [4]

Bring the diagnosis, cell source, route, sessions, baseline measurements, and planned follow-up. Human regeneration is limited and varies by tissue. [5] Less pain alone does not demonstrate that tissue has regrown. Ask what outcomes can be measured, over what period, and what findings should prompt specialist review.

Frequently asked questions

Do I need my local doctor’s permission before going?

Rules change by country and insurer, so this page cannot settle yours. Even so, tell your doctor before you go. That is how safety flags get raised, baseline tests get ordered, and follow-up gets an owner. Leave your return date too, so the follow-up is booked before you land.

Should my doctor write a referral letter?

Ask the receiving hospital or clinic whether it requires a referral. If your doctor writes one, include the diagnosis, key results, medicines, allergies, prior treatment, and reason for consultation. Keep it as baseline information alongside the return handover; it cannot replace the discharge summary.

What if the clinic only gives me Japanese documents?

Ask for an English summary of at least the discharge pages, the medicine list, and the follow-up plan. Keep it stapled to the Japanese, with world-readable dates, units, and reference ranges. If you arrange the translation yourself, clip the translator’s note to it and show your doctor both versions.

How soon should I see my local doctor after returning?

Before leaving Japan, ask the treating clinician to specify the next review date and required tests, then confirm an appointment with your local doctor. There is no single follow-up interval suitable for every cell procedure. Seek urgent care for warning signs rather than waiting for that appointment.

Your handover checklist

Before discharge, gather all 8 items: diagnosis, procedure note, cell product details, regulatory status, before-and-after medicine lists, key test results, follow-up plan with warning signs, and a contact for questions. After landing, hand the set to your local doctor at visit one, keep your copy, and agree what gets tracked, what rehab looks like, and what sends you to urgent care.

This is a document-preparation guide based on public regulatory and medical sources, not a treatment recommendation or an account of first-hand clinical practice. It cannot establish whether a particular intervention is safe or effective for you. A licensed clinician who knows your records should guide care decisions.

Planning treatment in Japan? Bring your diagnosis, medicine list, and travel dates, and ask the care team what paperwork your doctor at home will need.

Contact the care team

References

[1] Pharmaceuticals and Medical Devices Agency (Japan), Regenerative Medical Products. (Accessed November 13, 2026.)

[2] National Cancer Institute, Stem Cell and Bone Marrow Transplants for Cancer. (Accessed November 13, 2026.)

[3] Pharmaceuticals and Medical Devices Agency (Japan), Japan’s Regulatory Framework and Recent Updates on Regenerative Medical Products (presented May 20, 2026). (Slide deck presented May 20, 2026; record re-checked November 13, 2026.)

[4] U.S. Food and Drug Administration, Important Patient and Consumer Information About Regenerative Medicine Therapies. (Accessed November 13, 2026.)

[5] National Institute of General Medical Sciences, Regeneration. (Accessed November 13, 2026.)